New Report Calls for Collective Action to Combat Asia's Growing Antimicrobial Resistance Threat

The Centre for Impact Investing and Practices and the World Economic Forum's GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance, have released a study urging cross-sector investment to tackle antimicrobial resistance (AMR) in Asia.
AMR could cost Asia up to US$700 billion by 2050 and surpass cancer as the world's leading cause of death.
Report outlines four high-impact intervention areas – from education and prevention to surveillance and treatment – to guide funders and partners.
SINGAPORE - Media OutReach Newswire - 5 May 2025 - The Centre for Impact Investing and Practices (CIIP) and the World Economic Forum's GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance (PAA), today launched the report — Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia.
The report underscores the urgent threat of antimicrobial resistance (AMR) in Asia and outlines four key areas where cross-sector funders can drive meaningful impact. It draws on insights from 15 case studies and examples of funding mechanisms, and contributions from 26 organisations, including international organisations, corporations, philanthropic funders, public institutions, and solution providers.
Often called the silent pandemic, AMR was linked to 4.7 million deaths annually in 2021. [1] It is estimated to become the leading cause of death by 2050, claiming more than 8 million lives [2] and surpassing cancer [3]. Beyond human health, AMR threatens global food systems by reducing global livestock production and polluting waterways. Tackling this growing crisis requires a unified, whole-of-ecosystem approach.
"Antimicrobial resistance is a mounting crisis that threatens to reverse decades of medical progress, with Asia at the epicenter of this challenge. We have identified clear needs, but no single organisation can tackle this alone and substantial philanthropic and catalytic funding is required. It demands all actors — across sectors and borders — to step up, pool resources, and collaborate. Together, we hope that through active partnerships, we can build a future where effective treatments remain within everyone's reach," said Ms. Dawn Chan, Chief Executive Officer, CIIP.
"The Davos Compact on Antimicrobial Resistance (AMR), launched earlier in January this year, seeks to mobilise public-private-philanthropic, cross sectoral collaboration to reduce the global and increasing threat of AMR. This report builds on the Davos Compact, highlighting practical, high impact interventions where catalytic investments can help safeguard health and well-being, reducing risks and deaths associated with AMR," said Ms. Gim Huay Neo, Managing Director, Member of the Managing Board, World Economic Forum.
Asia: A Crucible for the Multifaceted AMR Challenge
Globally, nearly one in five AMR-related deaths occur in children under five [4], and two in three in adults over 65 [5]. However, Asia bears the brunt of the disease incidence, accounting for more than half of the 4.71 million deaths worldwide associated with AMR in 2021 [6]. Rising temperatures and extreme weather events are accelerating bacterial growth and disease transmission, while disrupting healthcare and immunisation services – particularly in regions with inadequate healthcare infrastructure and sanitation. These climate-related pressures are also driving the increased use of antimicrobials in livestock and crops, contaminating freshwater sources and fuelling drug resistance.
In Asia Pacific alone, AMR-related costs are projected to reach up to US$700 billion by 2050, accounting for up to 1% of the region's GDP [7]. However, timely investment in AMR solutions could generate US$10–15 billion in annual healthcare savings, and cut annual socio-economic costs by up to US$40 billion for Asia Pacific within the next decade. [8] Tackling AMR is essential for health security, as well as ensuring long-term economic resilience and sustainable development.
A Unified Approach to Antimicrobial Development and Use
Despite research advancements, market and policy gaps make it challenging to bring new drugs to patients as the costs involved in development and regulatory approval tend to outweigh the immediate returns upon product launch. A One Health approach — one that recognises the interconnectedness and interdependence across humans, animals, plants, and the wider environment — is essential to tackle AMR sustainably.
While new therapeutics such as drugs and vaccines can take 10 to 15 years to develop and launch to market [9] (a marathon), immediate and practical interventions (sprints) are needed to curb resistance today and pave the way for long-term solutions.
The report thus proposes interventions in four areas:
Sprint 1: Educate – Improving knowledge and behaviour by strengthening awareness of AMR among clinicians, patients, and farmers; emphasising the importance of avoiding the overuse or abuse of antimicrobials; as well as introducing strategies to prevent infections in the first place.
Sprint 2: Prevent – Strengthening health systems and services by boosting preventive measures such as improving diagnostic capabilities and investing in better water, sanitation, and hygiene (WASH) measures.
Sprint 3: Monitor – Enhancing regional surveillance, and data collection and sharing between actors, especially in lower-income countries.
Marathon: Treat – Investing in research and development for new antimicrobials, and increasing access to novel and essential medicines.
Financing AMR Solutions At Every Stage
Private funders, impact investors, and philanthropists have a vital role to play in closing critical gaps – particularly in late-stage drug development, where funding is scarce. By pooling resources, funders can help bring life-saving treatments to market, strengthen the antibiotic pipeline, and build more sustainable and widespread access to essential medicines.
"This report is a catalyst for deeper involvement from all sectors — philanthropic, public, and private. It highlights the scale of the AMR threat and the opportunity for collective action. We are encouraged by the ongoing work of organisations – including PAA members like the Gates Foundation, Wellcome Trust, and Novo Nordisk Foundation – in driving AMR research and greater access to affordable solutions. Now is the time for more partners to come together, pool resources, and support high-impact solutions that safeguard health and resilience across Asia and beyond," said Mr. Shaun Seow, Chief Executive Officer, PAA.
The AMR threat demands urgent, coordinated, and sustained action across healthcare, agriculture, and food systems to protect communities in Asia.
Read the full report here:
[1] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext
[2] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext
[3] Gavi (2022). Antimicrobial resistance now causes more deaths than HIV/AIDS and malaria worldwide – new study. 20 January 2022. Available at: https://www.gavi.org/vaccineswork/antimicrobial-resistance-now-causes-more-deaths-hivaids-and-malaria-worldwide-new.
[4] Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, Volume 399, Issue 10325, p629-655. https://www.google.com/url?q=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext%23supplementary-material&sa=D&source=docs&ust=1744866648294504&usg=AOvVaw0fopMXnonRugpe_OJ7JhIx
[5] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext
[6] Institute for Health Metrics and Evaluation (IHME). (2024). The Lancet: More than 39 million deaths from antibiotic-resistant infections estimated between now and 2050, suggests first global analysis. https://www.healthdata.org/news-events/newsroom/news-releases/lancet-more-39-million-deaths-antibiotic-resistant-infections.
[7] L.E.K. Consulting (2021) Asia-Pacific in the Eye of AMR Storm: Nurturing Innovation To Fight Antimicrobial Resistance. https://www.lek.com/sites/default/files/PDFs/Nurturing-Innovation-AMR-management.pdf?trk=article-ssr-frontend-pulse_little-text-block
[8] L.E.K. (2021). Asia-Pacific in the Eye of AMR Storm: Nurturing Innovation To Fight Antimicrobial Resistance. https://www.lek.com/sites/default/files/PDFs/Nurturing-Innovation-AMR-management.pdf
[9] Derep, M. (2022). What's the average time to bring a drug to market in 2022? N-Side. https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022.
The issuer is solely responsible for the content of this announcement.
About the Centre for Impact Investing and Practices
The Centre for Impact Investing and Practices (CIIP) was established in 2022 as a non-profit entity by Temasek Trust to foster impact investing and practices in Asia and beyond by building and sharing knowledge, bringing together stakeholders in the community, and bringing about positive action that accelerates the adoption of impact investing principles and practices. CIIP is the anchor partner for the United Nation Development Programme's Private Finance for the SDGs, providing Asia investors and businesses with clarity, insights and tools that support their contributions towards achieving the SDGs. Temasek and ABC Impact are CIIP's strategic partners. For more information, please visit www.ciip.com.sg.
About GAEA (Giving to Amplify Earth Action)
To reach net zero, reverse nature loss and restore biodiversity by 2050, funding for equitable climate and nature transitions must be stepped up by more than $3 trillion annually. No actor can solve these issues alone; only together – through partnerships, elevated ambition and accelerated learning – can the most pressing problems facing the planet be solved. The World Economic Forum launched the GAEA (Giving to Amplify Earth Action) initiative to convene 4P – Public, Private and Philanthropic Partnerships – for climate and nature, activating systemic bold partnerships to improve the state of the world.
About Philanthropy Asia Alliance
Philanthropy Asia Alliance (PAA) is a Temasek Trust initiative dedicated to catalysing collaborative philanthropy in Asia through dynamic multi-sector partnerships. By harnessing collective strengths, PAA multiplies impact, accelerates positive change, and takes urgent action to address the pressing environmental and social challenges of our time. PAA's flagship programme is the annual Philanthropy Asia Summit. For more information, visit http://philanthropyasiaalliance.org.
Centre for Impact Investing and Practices (CIIP), the World Economic Forum's GAEA (Giving to Amplify Earth Action) initiative, and the Philanthropy Asia Alliance (PAA)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Arabian Post

a day ago

• Arabian Post

AI‑Powered Phage Therapy Set to Tackle Antibiotic Resistance

Phagos, a Paris‑based biotech startup, is deploying an artificial‑intelligence model built on Amazon Web Services to accurately match bacteriophages with antibiotic‑resistant bacterial strains. This development marks a pivotal shift from arbitrary trial‑and‑error methods to precision medicine in combating infections that claim an estimated one million lives annually. The challenge of antibiotic resistance has spurred Phagos, co‑founded by microbiologist Adèle James and economist Alexandros Pantalis, to pursue alternative therapies. Phages are viruses that specifically infect bacteria, a property that enables targeted treatment without disrupting beneficial microorganisms. But identifying the right phage for a given pathogen has traditionally required labour‑intensive screening of millions of combinations. Phagos is leveraging AWS's Generative AI Accelerator Programme, which has provided them with cloud credits, embedded AWS architects and machine‑learning engineers, and dedicated mentorship, to build a generative AI platform capable of predicting effective pairings between phages and bacterial strains. The AI model has been trained on datasets from public repositories and proprietary lab results. ADVERTISEMENT 'We can now read into the DNA and see if there's going to be an interaction between a phage and a bacterium,' Pantalis explained. This capability bypasses exhaustive wet‑lab testing and accelerates the discovery pipeline. Phagos's strategy involves initial trials in animal health—shrimp, chicken, bovine, swine—with phages administered through water systems to curb infections in farm environments. James noted that reducing antibiotic use in livestock is critical, as drug‑resistant bacteria generated in farms can transfer to humans via environmental pathways. The startup's first validation came from a collaboration with an oyster farmer in France, where AI‑matched phages slashed mortality by 40 per cent. Technical infrastructure from AWS played a crucial role, with cloud experts helping to refine the system and scale it efficiently. 'We became much faster, and spent way less time figuring out how to set up our infrastructure,' James said. Globally, the antibiotic resistance crisis is projected to cause more deaths than cancer by mid‑century, with economic impacts exceeding US$1.5 trillion. By automating phage matching, Phagos aims to create personalised and adaptive therapies that evolve in tandem with bacterial mutations. Participation in AWS's 2024 accelerator—which selected just 80 startups from over 4,700 applicants—has provided Phagos not only with technical and financial support, but also exposure to industry networks and potential funding sources. The platform-as‑a‑service model being developed by Phagos positions the company as a pioneer in AI‑driven microbiological model building. One quarter of its team now focuses exclusively on data and machine learning, a rarity in biotech. Expansion plans are underway: the company intends to move into human therapeutic applications by 2030, while continuing its work in agriculture. It is also advancing bespoke phage therapies, distinguishing itself from generic phage cocktails pursued by competitors. While obstacles remain—such as regulatory pathways for phage-based treatments and the complexity of bacterial ecosystems—Phagos believes its AI model and cloud infrastructure provide a scalable solution. Each new phage cocktail generates data that feeds into the platform, enhancing future predictions.

Dubai Eye

2 days ago

• Dubai Eye

Death toll rises in Gaza as aid-seeking crowds come under fire

Dozens of Palestinians have been killed by Israeli fire in the past two days while trying to access food aid in Gaza, amid a worsening hunger crisis, according to local medics. On Thursday, medics reported at least 51 people killed by Israeli gunfire and airstrikes. Among them were 12 Palestinians who tried to approach a site operated by the US-backed Gaza Humanitarian Foundation (GHF) in the central part of the Strip. The incident is the latest in a string of deadly encounters involving civilians seeking food. The Israeli military said several individuals it described as "suspects" approached its forces near the Netzarim corridor in central Gaza in a way that endangered troops. It said soldiers fired warning shots to deter them and that it was not aware of any injuries at the time. Elsewhere in Gaza on Thursday, medics reported 39 people killed in separate Israeli airstrikes in the north of the territory. One strike on the Shati refugee camp in Gaza City killed at least 19 people, including women and children. Another strike killed at least 14 people in Jabalia and damaged several homes. There was no immediate comment from the Israeli army on those attacks. Gaza's health ministry said hundreds of Palestinians have been killed while trying to reach GHF distribution sites since late May. The United Nations has criticized the GHF's delivery system, calling it inadequate, dangerous and a violation of humanitarian impartiality. Israel defends the system as a necessary safeguard against diversion of aid by Hamas, a claim Hamas denies. GHF said Wednesday it had distributed 3 million meals across three sites in Gaza without incident. The war in Gaza began after Hamas launched a surprise attack on Israel on October 7, 2023, killing 1,200 people and taking 251 hostages, according to Israeli figures. Israel's ongoing military campaign has since killed nearly 55,600 Palestinians, according to Gaza's health ministry, displaced nearly the entire population of over 2 million, and left much of the territory in humanitarian collapse.

Middle East Eye

5 days ago

• Middle East Eye

Tuesday death toll in Gaza rises to 89

At least 89 Palestinians have been killed in Israeli attacks across Gaza since dawn, with at least 80 killed in Israeli ambushes at US-run aid distribution centres in Khan Younis and Rafah, the Palestinian health ministry has said in a statement. The attacks occurred as residents gathered at aid distribution points, where they came under artillery shelling from Israeli forces.